Page last updated: 2024-12-06

urobilinogen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Urobilinogen is a colorless compound produced in the intestines from the breakdown of bilirubin. Bilirubin is a yellow pigment produced from the breakdown of heme, a component of red blood cells. Urobilinogen is absorbed into the bloodstream and excreted in urine and feces. Increased levels of urobilinogen in urine or feces may indicate liver disease, hemolytic anemia, or other conditions.'

Urobilinogen: A colorless compound formed in the intestines by the reduction of bilirubin. Some is excreted in the feces where it is oxidized to urobilin. Some is reabsorbed and re-excreted in the bile as bilirubin. At times, it is re-excreted in the urine, where it may be later oxidized to urobilin. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

urobilinogen : A member of the class of bilanes that is a colourless product formed in the intestine by the reduction of bilirubin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID26818
CHEBI ID29026
SCHEMBL ID132233
MeSH IDM0022380

Synonyms (26)

Synonym
2,17-diethyl-3,7,13,18-tetramethyl-1,19-dioxo-1,4,5,10,15,16,19,22,23,24-decahydro-21h-biline-8,12-dipropanoic acid
CHEBI:29026
mesobilirubinogen ixalpha
2,17-diethyl-1,4,5,10,15,16,19,22,23,24-decahydro-3,7,13,18-tetramethyl-1,19-dioxo-21h-biline-8,12-dipropanoic acid
urobilinogen ixalpha
8,12-bis(2-carboxyethyl)-3,18-diethyl-2,7,13,17-tetramethylbilane-1,19(4h,16h)-dione
21h-biline-8,12-dipropanoic acid, 2,17-diethyl-1,4,5,10,15,16,19,22,23,24-decahydro-3,7,13,18-tetramethyl-1,19-dioxo-
biline-8,12-dipropionic acid, 2,17-diethyl-1,4,5,10,15,16,19,22,23,24-decahydro-3,7,13,18-tetramethyl-1,19-dioxo-
i-urobilinogen
14684-37-8
mesobilirubinogen
C05790
urobilinogen
3-[2-[[3-(2-carboxyethyl)-5-[(3-ethyl-4-methyl-5-oxo-1,2-dihydropyrrol-2-yl)methyl]-4-methyl-1h-pyrrol-2-yl]methyl]-5-[(4-ethyl-3-methyl-5-oxo-1,2-dihydropyrrol-2-yl)methyl]-4-methyl-1h-pyrrol-3-yl]propanoic acid
py8n5v3s0d ,
unii-py8n5v3s0d
SCHEMBL132233
3-(2-{[3-(2-carboxyethyl)-5-[(4-ethyl-3-methyl-5-oxo-2,5-dihydro-1h-pyrrol-2-yl)methyl]-4-methyl-1h-pyrrol-2-yl]methyl}-5-[(3-ethyl-4-methyl-5-oxo-2,5-dihydro-1h-pyrrol-2-yl)methyl]-4-methyl-1h-pyrrol-3-yl)propanoic acid
2,17-diethyl-1,4,5,10,15,16,19,22,23,24-decahydro-3,7,13,18-tetramethyl-1,19-dioxo-biline-8,12-dipropionic acid
J-008273
Q57054
urinary urobilinogen
DTXSID601105823
3-(2-((3-(2-carboxyethyl)-5-((3-ethyl-4-methyl-5-oxo-2,5-dihydro-1h-pyrrol-2-yl)methyl)-4-methyl-1h-pyrrol-2-yl)methyl)-5-((4-ethyl-3-methyl-5-oxo-2,5-dihydro-1h-pyrrol-2-yl)methyl)-4-methyl-1h-pyrrol-3-yl)propanoic acid
21h-biline-8,12-dipropanoic acid, 2,17-diethyl-1,4,5,10,15,16,19,22,23,24-decahydro-3,7,13,18-tetramethyl-1,19-dioxo- (9ci)
PD057089

Research Excerpts

Overview

Urobilinogen is a weak acid, and this mode of excretion is similar to that of other weak, organic acids, such as salicylates.

ExcerptReferenceRelevance
"Urobilinogen is a weak acid, and this mode of excretion is similar to that of other weak, organic acids, such as salicylates."( Renal excretion of urobilinogen in the dog.
Lester, R; Levinsky, NG; Levy, M, 1968
)
1.3

Dosage Studied

ExcerptRelevanceReference
" The studied drugs were administered orally in standard dosage for six days to groups of six volunteers."( Faecal level of urobilinogen: an indication for the risk of superinfection and of failure of oral anticonception?
Clasener, HA; Jankowiak, MM; Muller, NF; Vollaard, EJ, 1989
)
0.62
" Male rats dosed at 24 x 10(6) IU/kg showed the decrease of the absolute kidney weights and the increase of the brain relative weights."( A 4-week subcutaneous toxicity study of recombinant human interferon alpha A (LBD-007) in Sprague-Dawley rats.
Ha, CS; Han, SS; Kang, BH; Kim, HC; Roh, JK, 1993
)
0.29
" Similarly, ophthalmic changes (lenticular clouding) were observed in both control and dosed animals."( Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): V. A 13-week toxicity study of tripeptides-containing casein hydrolysate in male and female rats.
Bernard, BK; Matsuura, K; Mennear, JH; Mizuno, S, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
bilanes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (354)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990309 (87.29)18.7374
1990's21 (5.93)18.2507
2000's9 (2.54)29.6817
2010's12 (3.39)24.3611
2020's3 (0.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 99.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index99.96 (24.57)
Research Supply Index5.95 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index181.75 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (99.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.79%)5.53%
Reviews23 (6.08%)6.00%
Case Studies13 (3.44%)4.05%
Observational0 (0.00%)0.25%
Other339 (89.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]